Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Glycosylated sphingolipids and progression to kidney dysfunction in type 1 diabetes.

Lopes-Virella MF, Baker NL, Hunt KJ, Hammad SM, Arthur J, Virella G, Klein RL; DCCT/EDIC Research Group.

J Clin Lipidol. 2019 Apr 3. pii: S1933-2874(19)30047-9. doi: 10.1016/j.jacl.2019.03.005. [Epub ahead of print]

PMID:
31043336
2.

Methods to reduce the incidence of false negative trial results in substance use treatment research.

Tomko RL, McClure EA, Squeglia LM, Treloar Padovano H, McRae-Clark AL, Baker NL, Carpenter MJ, Gray KM.

Curr Opin Psychol. 2019 Jan 28;30:35-41. doi: 10.1016/j.copsyc.2019.01.009. [Epub ahead of print] Review.

PMID:
30798020
3.

Gender differences in subjective stress and neuroendocrine response to a stress task among individuals with opioid dependence: A pilot study.

Gilmore AK, Guille C, Baker NL, Brady KT, Hahn CK, Davis CM, McCauley JL, Back SE.

Addict Behav. 2019 May;92:148-154. doi: 10.1016/j.addbeh.2018.12.022. Epub 2019 Jan 5.

PMID:
30640146
4.

Sex Differences in Subjective and Behavioral Responses to Stressful and Smoking Cues Presented in the Natural Environment of Smokers.

Tomko RL, Saladin ME, Baker NL, McClure EA, Carpenter MJ, Ramakrishnan VR, Heckman BW, Wray JM, Foster KT, Tiffany ST, Metts CL, Gray KM.

Nicotine Tob Res. 2018 Oct 26. doi: 10.1093/ntr/nty234. [Epub ahead of print]

PMID:
30371887
5.

Tobacco use during cannabis cessation: Use patterns and impact on abstinence in a National Drug Abuse Treatment Clinical Trials Network study.

McClure EA, Baker NL, Sonne SC, Ghitza UE, Tomko RL, Montgomery L, Babalonis S, Terry GE, Gray KM.

Drug Alcohol Depend. 2018 Nov 1;192:59-66. doi: 10.1016/j.drugalcdep.2018.07.018. Epub 2018 Aug 25.

6.

Biological correlates of self-reported new and continued abstinence in cannabis cessation treatment clinical trials.

Baker NL, Gray KM, Sherman BJ, Morella K, Sahlem GL, Wagner AM, McRae-Clark AL.

Drug Alcohol Depend. 2018 Jun 1;187:270-277. doi: 10.1016/j.drugalcdep.2018.03.017. Epub 2018 Apr 16.

7.

Intolerance for smoking abstinence among nicotine-deprived, treatment-seeking smokers.

Germeroth LJ, Baker NL, Saladin ME.

Addict Behav. 2018 Sep;84:13-19. doi: 10.1016/j.addbeh.2018.03.019. Epub 2018 Mar 20.

PMID:
29597136
8.

Approach bias modification for cannabis use disorder: A proof-of-principle study.

Sherman BJ, Baker NL, Squeglia LM, McRae-Clark AL.

J Subst Abuse Treat. 2018 Apr;87:16-22. doi: 10.1016/j.jsat.2018.01.012. Epub 2018 Jan 16.

9.

The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial.

Squeglia LM, Tomko RL, Baker NL, McClure EA, Book GA, Gray KM.

Drug Alcohol Depend. 2018 Apr 1;185:17-22. doi: 10.1016/j.drugalcdep.2017.12.005. Epub 2018 Feb 1.

10.

Monoallelic BMP2 Variants Predicted to Result in Haploinsufficiency Cause Craniofacial, Skeletal, and Cardiac Features Overlapping Those of 20p12 Deletions.

Tan TY, Gonzaga-Jauregui C, Bhoj EJ, Strauss KA, Brigatti K, Puffenberger E, Li D, Xie L, Das N, Skubas I, Deckelbaum RA, Hughes V, Brydges S, Hatsell S, Siao CJ, Dominguez MG, Economides A, Overton JD, Mayne V, Simm PJ, Jones BO, Eggers S, Le Guyader G, Pelluard F, Haack TB, Sturm M, Riess A, Waldmueller S, Hofbeck M, Steindl K, Joset P, Rauch A, Hakonarson H, Baker NL, Farlie PG.

Am J Hum Genet. 2017 Dec 7;101(6):985-994. doi: 10.1016/j.ajhg.2017.10.006. Epub 2017 Nov 30.

11.

Impact of endogenous progesterone on reactivity to yohimbine and cocaine cues in cocaine-dependent women.

Moran-Santa Maria MM, Sherman BJ, Brady KT, Baker NL, Hyer JM, Ferland C, McRae-Clark AL.

Pharmacol Biochem Behav. 2018 Feb;165:63-69. doi: 10.1016/j.pbb.2017.11.001. Epub 2017 Nov 7.

12.

Association Between Inflammatory Markers and Progression to Kidney Dysfunction: Examining Different Assessment Windows in Patients With Type 1 Diabetes.

Baker NL, Hunt KJ, Stevens DR, Jarai G, Rosen GD, Klein RL, Virella G, Lopes-Virella MF; DCCT/EDIC Research Group.

Diabetes Care. 2018 Jan;41(1):128-135. doi: 10.2337/dc17-0867. Epub 2017 Nov 8.

13.

Incremental validity of estimated cannabis grams as a predictor of problems and cannabinoid biomarkers: Evidence from a clinical trial.

Tomko RL, Baker NL, McClure EA, Sonne SC, McRae-Clark AL, Sherman BJ, Gray KM.

Drug Alcohol Depend. 2018 Jan 1;182:1-7. doi: 10.1016/j.drugalcdep.2017.09.035. Epub 2017 Nov 2.

14.

Repetitive transcranial magnetic stimulation (rTMS) administration to heavy cannabis users.

Sahlem GL, Baker NL, George MS, Malcolm RJ, McRae-Clark AL.

Am J Drug Alcohol Abuse. 2018;44(1):47-55. doi: 10.1080/00952990.2017.1355920. Epub 2017 Aug 14.

15.

Rationale, design, and implementation of a clinical trial of a mindfulness-based relapse prevention protocol for the treatment of women with comorbid post traumatic stress disorder and substance use disorder.

Vrana C, Killeen T, Brant V, Mastrogiovanni J, Baker NL.

Contemp Clin Trials. 2017 Oct;61:108-114. doi: 10.1016/j.cct.2017.07.024. Epub 2017 Jul 29.

16.

Co-option of the cardiac transcription factor Nkx2.5 during development of the emu wing.

Farlie PG, Davidson NM, Baker NL, Raabus M, Roeszler KN, Hirst C, Major A, Mariette MM, Lambert DM, Oshlack A, Smith CA.

Nat Commun. 2017 Jul 25;8(1):132. doi: 10.1038/s41467-017-00112-7.

17.

A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults.

Gray KM, Sonne SC, McClure EA, Ghitza UE, Matthews AG, McRae-Clark AL, Carroll KM, Potter JS, Wiest K, Mooney LJ, Hasson A, Walsh SL, Lofwall MR, Babalonis S, Lindblad RW, Sparenborg S, Wahle A, King JS, Baker NL, Tomko RL, Haynes LF, Vandrey RG, Levin FR.

Drug Alcohol Depend. 2017 Aug 1;177:249-257. doi: 10.1016/j.drugalcdep.2017.04.020. Epub 2017 Jun 10.

18.

Effect of oxytocin pretreatment on cannabis outcomes in a brief motivational intervention.

Sherman BJ, Baker NL, McRae-Clark AL.

Psychiatry Res. 2017 Mar;249:318-320. doi: 10.1016/j.psychres.2017.01.027. Epub 2017 Jan 20.

19.

Gender differences among treatment-seeking adults with cannabis use disorder: Clinical profiles of women and men enrolled in the achieving cannabis cessation-evaluating N-acetylcysteine treatment (ACCENT) study.

Sherman BJ, McRae-Clark AL, Baker NL, Sonne SC, Killeen TK, Cloud K, Gray KM.

Am J Addict. 2017 Mar;26(2):136-144. doi: 10.1111/ajad.12503. Epub 2017 Feb 2.

20.

Effect of a Brief Memory Updating Intervention on Smoking Behavior: A Randomized Clinical Trial.

Germeroth LJ, Carpenter MJ, Baker NL, Froeliger B, LaRowe SD, Saladin ME.

JAMA Psychiatry. 2017 Mar 1;74(3):214-223. doi: 10.1001/jamapsychiatry.2016.3148.

21.

Clinical and Molecular Characterisation of Children with Pierre Robin Sequence and Additional Anomalies.

Xu JX, Kilpatrick N, Baker NL, Penington A, Farlie PG, Tan TY.

Mol Syndromol. 2016 Nov;7(6):322-328. Epub 2016 Sep 15.

22.

Frontonasal Dysplasia: Towards an Understanding of Molecular and Developmental Aetiology.

Farlie PG, Baker NL, Yap P, Tan TY.

Mol Syndromol. 2016 Nov;7(6):312-321. Epub 2016 Oct 29. Review.

23.

Alcohol consumption as a predictor of reactivity to smoking and stress cues presented in the natural environment of smokers.

Tomko RL, Saladin ME, McClure EA, Squeglia LM, Carpenter MJ, Tiffany ST, Baker NL, Gray KM.

Psychopharmacology (Berl). 2017 Feb;234(3):427-435. doi: 10.1007/s00213-016-4472-x. Epub 2016 Nov 12.

24.

Alcohol use during a trial of N-acetylcysteine for adolescent marijuana cessation.

Squeglia LM, Baker NL, McClure EA, Tomko RL, Adisetiyo V, Gray KM.

Addict Behav. 2016 Dec;63:172-7. doi: 10.1016/j.addbeh.2016.08.001. Epub 2016 Aug 4.

25.

Increased Plasma Levels of Select Deoxy-ceramide and Ceramide Species are Associated with Increased Odds of Diabetic Neuropathy in Type 1 Diabetes: A Pilot Study.

Hammad SM, Baker NL, El Abiad JM, Spassieva SD, Pierce JS, Rembiesa B, Bielawski J, Lopes-Virella MF, Klein RL; DCCT/EDIC Group of Investigators.

Neuromolecular Med. 2017 Mar;19(1):46-56. doi: 10.1007/s12017-016-8423-9. Epub 2016 Jul 7.

26.

Gender differences in cannabis use disorder treatment: Change readiness and taking steps predict worse cannabis outcomes for women.

Sherman BJ, Baker NL, McRae-Clark AL.

Addict Behav. 2016 Sep;60:197-202. doi: 10.1016/j.addbeh.2016.04.014. Epub 2016 Apr 22.

27.

Effects of yohimbine and drug cues on impulsivity and attention in cocaine-dependent men and women and sex-matched controls.

Moran-Santa Maria MM, Baker NL, McRae-Clark AL, Prisciandaro JJ, Brady KT.

Drug Alcohol Depend. 2016 May 1;162:56-63. doi: 10.1016/j.drugalcdep.2016.02.021. Epub 2016 Feb 23.

28.

High levels of AGE-LDL, and of IgG antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDA-LDL in circulating immune complexes predict macroalbuminuria in patients with type 2 diabetes.

Lopes-Virella MF, Hunt KJ, Baker NL, Virella G; VADT Group of Investigators.

J Diabetes Complications. 2016 May-Jun;30(4):693-9. doi: 10.1016/j.jdiacomp.2016.01.012. Epub 2016 Jan 14.

PMID:
26861948
29.

Vilazodone for cannabis dependence: A randomized, controlled pilot trial.

McRae-Clark AL, Baker NL, Gray KM, Killeen T, Hartwell KJ, Simonian SJ.

Am J Addict. 2016 Jan;25(1):69-75. doi: 10.1111/ajad.12324. Epub 2015 Dec 20.

30.

Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial.

McRae-Clark AL, Baker NL, Gray KM, Killeen TK, Wagner AM, Brady KT, DeVane CL, Norton J.

Drug Alcohol Depend. 2015 Nov 1;156:29-37. doi: 10.1016/j.drugalcdep.2015.08.013. Epub 2015 Aug 25.

31.

Effects of adverse childhood experiences on the association between intranasal oxytocin and social stress reactivity among individuals with cocaine dependence.

Flanagan JC, Baker NL, McRae-Clark AL, Brady KT, Moran-Santa Maria MM.

Psychiatry Res. 2015 Sep 30;229(1-2):94-100. doi: 10.1016/j.psychres.2015.07.064. Epub 2015 Jul 23.

32.

Olfr603, an orphan olfactory receptor, is expressed in multiple specific embryonic tissues.

Baker NL, Miller KA, Newgreen DF, Farlie PG.

Gene Expr Patterns. 2015 Sep-Nov;19(1-2):30-5. doi: 10.1016/j.gep.2015.06.002. Epub 2015 Jun 23.

PMID:
26116001
33.

Concordance of Direct and Indirect Measures of Medication Adherence in A Treatment Trial for Cannabis Dependence.

McRae-Clark AL, Baker NL, Sonne SC, DeVane CL, Wagner A, Norton J.

J Subst Abuse Treat. 2015 Oct;57:70-4. doi: 10.1016/j.jsat.2015.05.002. Epub 2015 May 7.

34.

Longitudinal Association Between Endothelial Dysfunction, Inflammation, and Clotting Biomarkers With Subclinical Atherosclerosis in Type 1 Diabetes: An Evaluation of the DCCT/EDIC Cohort.

Hunt KJ, Baker NL, Cleary PA, Klein R, Virella G, Lopes-Virella MF; DCCT/EDIC Group of Investigators.

Diabetes Care. 2015 Jul;38(7):1281-9. doi: 10.2337/dc14-2877. Epub 2015 Apr 7.

35.

Increasing progesterone levels are associated with smoking abstinence among free-cycling women smokers who receive brief pharmacotherapy.

Saladin ME, McClure EA, Baker NL, Carpenter MJ, Ramakrishnan V, Hartwell KJ, Gray KM.

Nicotine Tob Res. 2015 Apr;17(4):398-406. doi: 10.1093/ntr/ntu262.

36.

An exploratory short-term double-blind randomized trial of varenicline versus nicotine patch for smoking cessation in women.

Gray KM, McClure EA, Baker NL, Hartwell KJ, Carpenter MJ, Saladin ME.

Addiction. 2015 Jun;110(6):1027-34. doi: 10.1111/add.12895. Epub 2015 Mar 29.

37.

Cognitive performance in a placebo-controlled pharmacotherapy trial for youth with marijuana dependence.

Roten A, Baker NL, Gray KM.

Addict Behav. 2015 Jun;45:119-23. doi: 10.1016/j.addbeh.2015.01.013. Epub 2015 Jan 23.

38.

The predictive role of markers of Inflammation and endothelial dysfunction on the course of diabetic retinopathy in type 1 diabetes.

Rajab HA, Baker NL, Hunt KJ, Klein R, Cleary PA, Lachin J, Virella G, Lopes-Virella MF; DCCT/EDIC Group of Investigators.

J Diabetes Complications. 2015 Jan-Feb;29(1):108-14. doi: 10.1016/j.jdiacomp.2014.08.004. Epub 2014 Aug 20.

39.

Impact of acute guanfacine administration on stress and cue reactivity in cocaine-dependent individuals.

Moran-Santa Maria MM, Baker NL, Ramakrishnan V, Brady KT, McRae-Clark A.

Am J Drug Alcohol Abuse. 2015 Mar;41(2):146-52. doi: 10.3109/00952990.2014.945590. Epub 2014 Aug 20.

40.

Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes.

Klein RL, Hammad SM, Baker NL, Hunt KJ, Al Gadban MM, Cleary PA, Virella G, Lopes-Virella MF; DCCT/EDIC Research Group.

Metabolism. 2014 Oct;63(10):1287-95. doi: 10.1016/j.metabol.2014.07.001. Epub 2014 Jul 9.

41.

An open-label pilot trial of N-acetylcysteine and varenicline in adult cigarette smokers.

McClure EA, Baker NL, Gipson CD, Carpenter MJ, Roper AP, Froeliger BE, Kalivas PW, Gray KM.

Am J Drug Alcohol Abuse. 2015 Jan;41(1):52-6. doi: 10.3109/00952990.2014.933839. Epub 2014 Jul 25.

42.

Cigarette smoking during an N-acetylcysteine-assisted cannabis cessation trial in adolescents.

McClure EA, Baker NL, Gray KM.

Am J Drug Alcohol Abuse. 2014 Jul;40(4):285-91. doi: 10.3109/00952990.2013.878718. Epub 2014 Apr 10.

43.

Yohimbine administration and cue-reactivity in cocaine-dependent individuals.

Moran-Santa Maria MM, McRae-Clark A, Baker NL, Ramakrishnan V, Brady KT.

Psychopharmacology (Berl). 2014 Oct;231(21):4157-65. doi: 10.1007/s00213-014-3555-9. Epub 2014 Apr 8.

44.

Response to comment on Lopes-Virella et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes care 2013;36:2317-2323.

Lopes-Virella MF, Baker NL, Hunt KJ, Cleary PA, Klein R, Virella G; DCCT/EDIC Research Group.

Diabetes Care. 2014 May;37(5):e108-9. doi: 10.2337/dc13-2976. Epub 2014 Feb 4. No abstract available.

45.

Smoking topography and abstinence in adult female smokers.

McClure EA, Saladin ME, Baker NL, Carpenter MJ, Gray KM.

Addict Behav. 2013 Dec;38(12):2833-6. doi: 10.1016/j.addbeh.2013.08.004. Epub 2013 Aug 17.

46.

Preoperative steroid treatment does not improve markers of inflammation after cardiac surgery in neonates: results from a randomized trial.

Graham EM, Atz AM, McHugh KE, Butts RJ, Baker NL, Stroud RE, Reeves ST, Bradley SM, McGowan FX Jr, Spinale FG.

J Thorac Cardiovasc Surg. 2014 Mar;147(3):902-8. doi: 10.1016/j.jtcvs.2013.06.010. Epub 2013 Jul 16.

47.

Apolipoprotein-defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort.

Jenkins AJ, Yu J, Alaupovic P, Basu A, Klein RL, Lopes-Virella M, Baker NL, Hunt KJ, Lackland DT, Garvey WT, Lyons TJ; DCCT/EDIC Research Group.

J Diabetes Complications. 2013 Sep-Oct;27(5):447-53. doi: 10.1016/j.jdiacomp.2013.06.002. Epub 2013 Jul 11.

48.

Modeling longitudinal drinking data in clinical trials: an application to the COMBINE study.

DeSantis SM, Bandyopadhyay D, Baker NL, Randall PK, Anton RF, Prisciandaro JJ.

Drug Alcohol Depend. 2013 Sep 1;132(1-2):244-50. doi: 10.1016/j.drugalcdep.2013.02.013. Epub 2013 Apr 6.

49.

Effect of oxytocin on craving and stress response in marijuana-dependent individuals: a pilot study.

McRae-Clark AL, Baker NL, Maria MM, Brady KT.

Psychopharmacology (Berl). 2013 Aug;228(4):623-31. doi: 10.1007/s00213-013-3062-4. Epub 2013 Apr 6.

50.

Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects.

Lopes-Virella MF, Baker NL, Hunt KJ, Cleary PA, Klein R, Virella G; DCCT/EDIC Research Group.

Diabetes Care. 2013 Aug;36(8):2317-23. doi: 10.2337/dc12-2521. Epub 2013 Mar 20.

Supplemental Content

Loading ...
Support Center